Lipocine is a pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. Co.'s key product candidate, TLANDO, is an oral testosterone replacement therapy. Additional pipeline candidates include LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of non-alcoholic steatohepatitis (NASH); TLANDO XR( LPCN 1111), an oral testosterone therapy product with the potential for once daily dosing; LPCN 1148, an oral prodrug of bioidentical testosterone for the treatment of NASH cirrhosis; and an oral therapy for the prevention of preterm birth, LPCN 1107. The LPCN stock yearly return is shown above.
The yearly return on the LPCN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the LPCN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|